Stimuli-Responsive Nanoparticles for Pharmaceutical Application in Cancer

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Nanomedicine and Nanotechnology".

Deadline for manuscript submissions: closed (30 April 2023) | Viewed by 2251

Special Issue Editors


E-Mail
Guest Editor
1. School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin (TCD), Dublin 2, Ireland
2. Trinity Biomedical Sciences Institute, Trinity College Dublin (TCD), Dublin 2, Ireland
Interests: mesoporous silica nanoparticles; stimuli-responsive nanosystems; targeted drug delivery
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, Dublin 2, Ireland
Interests: porous nanoparticles; hydrogels; triggered drug release; nanotheranostics
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Stimuli-responsive nanocarriers for the controlled release of encapsulated cargo represent a powerful tool to minimize the risk of systemic exposure of non-target tissues to drugs, thus avoiding undesired side effects and drug–plasma interactions, and to increase the site-specific concentration of a drug or of a signalling molecule. The ability of a nanosystem to modify its physicochemical properties in response to external stimuli or environmental conditions, producing a variation in its structure or function, perfectly illustrates the concept of nanostructures as defined by the EMA in the following terms: a system with specific properties that are not obtainable with its isolated individual components, and that confer clinical advantages.

This Special Issue’s goal is to highlight current progress in the development of anti-tumour therapeutic strategies based on stimuli-responsive nanocarriers. We invite review or original articles on all aspects of “Stimuli-Responsive Nanoparticles for Pharmaceutical Application in Cancer”.

Dr. Amelia Ultimo
Dr. Eduardo Ruiz-Hernandez
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • nanomedicine
  • stimuli-responsive nanoparticles
  • drug/gene delivery systems
  • cancer therapy

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

15 pages, 2567 KiB  
Article
In Situ-Forming Gels Loaded with Stimuli-Responsive Gated Mesoporous Silica Nanoparticles for Local Sustained Drug Delivery
by Cristina de la Torre, Carmen Coll, Amelia Ultimo, Félix Sancenón, Ramón Martínez-Máñez and Eduardo Ruiz-Hernández
Pharmaceutics 2023, 15(4), 1071; https://0-doi-org.brum.beds.ac.uk/10.3390/pharmaceutics15041071 - 26 Mar 2023
Cited by 3 | Viewed by 2011
Abstract
A novel combination of in situ-forming hydrogels of hyaluronic acid with gated mesoporous materials was developed to design depots for local sustained release of chemotherapeutics. The depot consists of a hyaluronic-based gel loaded with redox-responsive mesoporous silica nanoparticles loaded with safranin O or [...] Read more.
A novel combination of in situ-forming hydrogels of hyaluronic acid with gated mesoporous materials was developed to design depots for local sustained release of chemotherapeutics. The depot consists of a hyaluronic-based gel loaded with redox-responsive mesoporous silica nanoparticles loaded with safranin O or doxorubicin and capped with polyethylene glycol chains containing a disulfide bond. The nanoparticles are able to deliver the payload in the presence of the reducing agent, glutathione (GSH), that promotes the cleavage of the disulfide bonds and the consequent pore opening and cargo delivery. Release studies and cellular assays demonstrated that the depot can successfully liberate the nanoparticles to the media and, subsequently, that the nanoparticles are internalized into the cells where the high concentration of GSH induces cargo delivery. When the nanoparticles were loaded with doxorubicin, a significant reduction in cell viability was observed. Our research opens the way to the development of new depots that enhance the local controlled release of chemotherapeutics by combining the tunable properties of hyaluronic gels with a wide range of gated materials. Full article
Show Figures

Figure 1

Back to TopTop